Targeting of Metabotropic Glutamate Receptors for the Development of Novel Antidepressants. (April 2019)

• Record Type: Journal Article
• Authors: Chaki, Shigeyuki; Koike, Hiroyuki; Fukumoto, Kenichi
• Is Part Of: Chronic stress. Volume 3(2019)
• Publication Date: 2019-04
• Subjects: mGlu2 receptor -- mGlu3 receptor -- mGlu4 receptor -- mGlu5 receptor -- mGlu7 receptor -- antidepressant -- ketamine; Stress (Psychology) -- Periodicals; Stress (Physiology) -- Periodicals; Stress (Physiology); Stress, Psychological -- therapy; Stress, Physiological; Mental Disorders -- etiology; Electronic journals; Periodicals; Periodicals; 616.89
• DOI: 10.1177/2470547019837712
• Languages: English
• ISSNs: 2470-5470

Abstract

Since discovering that ketamine has robust antidepressant effects, the glutamatergic system has been proposed as an attractive target for the development of novel antidepressants. Among the glutamatergic system, metabotropic glutamate (mGlu) receptors are of interest because mGlu receptors play modulatory roles in glutamatergic transmission, consequently, agents acting on mGlu receptors might not exert the adverse effects associated with ketamine. mGlu receptors have eight subtypes that are classified into three groups, and the roles of each mGlu receptor subtype in depression are being investigated. To date, the potential use of mGlu5 receptor antagonists and mGlu2/3 receptor antagonists as antidepressants has been actively investigated, and the mechanisms underlying these antidepressant effects are being delineated. Although the outcomes of clinical trials using an mGlu5 receptor negative allosteric modulator and an mGlu2/3 receptor negative allosteric modulator have not been encouraging, these trials have been inconclusive, and additional trials using other compounds with more appropriate profiles are needed. In contrast, the roles of group III mGlu receptors have not yet been fully elucidated because of a lack of suitable pharmacological tools. Nonetheless, investigations of the use of mGlu4 and mGlu7 receptors as drug targets for the development of antidepressants have been ongoing, and some interesting evidence has been obtained.